# RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms

Source: https://onco.cc/trials/nct06243458/  
OnCo record `nct06243458` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of RVU120 (SEL120) in myelodysplastic syndromes / neoplasms, run by GCP-Service International West GmbH, active and no longer recruiting.

## Summary

RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms is a phase 2 interventional study registered as NCT06243458 by GCP-Service International West GmbH, with 41 participants enrolled, started 2024-09-10 and due to reach its primary completion in 2026-05. Interventions recorded: RVU120 (SEL120).

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06243458
- Phase: 2
- Setting: A Phase II, Open-label, Multicenter Study of Orally Administered RVU120 for the Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms (MDS)
- Sponsor: GCP-Service International West GmbH
- Enrolled: 41

## Sources

- ClinicalTrials.gov NCT06243458: https://clinicaltrials.gov/study/NCT06243458

## Connected records

- cancers: [Myelodysplastic syndromes / neoplasms (MDS)](https://onco.cc/cancers/mds/)
- companies: [Ryvu Therapeutics](https://onco.cc/companies/ryvu-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct06243458.json